

**U.S.S.N. 09/127,138
GRUENBERG
SUPPLEMENTAL AMENDMENT**

REMARKS

Any fee that may be due in connection with this application may be charged to Deposit Account No. 50-1213. If a Petition for extension of time is needed, this paper is to be considered such Petition.


Claims 48, 51, 124, 126 and 127 are presently pending. Claims 124 and 126 are amended herein. These amendments replace the amendments submitted in the 11/13/00 response, and include the amendment to portions of the claim which were inadvertently not underlined or did not include a previously amended claim dependency. Claims 124 and 126 as amended herein, properly reflect the intended amendments.

* * *

In view of the above remarks and the amendments and remarks of record, consideration and allowance of the application are respectfully requested.

Respectfully submitted,
HELLER EHRMAN WHITE & MCAULIFFE LLP

By:


Stephanie Seidman
Registration No. 33,779

Attorney Docket No. 24731-500E
Address all correspondence to:
HELLER EHRMAN WHITE & MCAULIFFE LLP
4350 La Jolla Village Drive, Suite 600
San Diego, CA 92122-1246
Telephone: 858 450-8400
Facsimile: 858 587-5360
EMAIL: sseidman@HEWM.com

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: MICHEAL L. GRUENBERG

Serial No.: 09/127,138


Filed: July 31, 1998

For: AUTOLOGOUS IMMUNE CELL
THERAPY: CELL COMPOSITIONS,
METHODS AND APPLICATIONS TO
TREATMENT OF HUMAN DISEASE

Art Unit: 1644

Examiner: Schwadron, R

I hereby certify that this paper and the attached
papers are being deposited with the United States
Postal Service as first class mail in an envelope
addressed to:
Commissioner for Patents
Washington, D.C. 20231, on this date.

10/10/01
Date
Kelly FisherATTACHMENT TO THE SUPPLEMENTAL RESPONSE
MARKED UP PARAGRAPHS AND CLAIMS (37 CFR §1.121)

IN THE CLAIMS:


Please amend claim 124 and 126 as follows:

124. (Amended) A method for altering the regulatory balance of immune cells in a human, comprising administering to the human a composition comprising [a clinically relevant number] at least 10^{10} Th1 cells of autologous regulatory T-cells].

126. (Twice Amended) The method of claim [124] 48, wherein at least [10^{10}] 10^{11} cells are [administered] reinfused.

Respectfully submitted,
HELLER EHRMAN WHITE & MCAULIFFE LLP

By:


Stephanie Seidman
Registration No. 33,779

Attorney Docket No. 24731-500E
Address all correspondence to:
HELLER EHRMAN WHITE & MCAULIFFE LLP
4350 La Jolla Village Drive, Suite 600
San Diego, CA 92122-1246
Telephone: 858 450-8400
Facsimile: 858 587-5360
EMAIL:sseidman@HEWM.com